The Moon Phase

[PoemStone]

glassy. How's this for a board change.

[PoemStone]

Just as on Sleepers! the logo is linked to info
and the 'marks' beside them are linked to a chart.

[PoemStone]

PERL [Poemstone] 2ndly.

[PoemStone]

Our 1st ticker TOOT moved from Sleepers!.
Keeping the picks at 99 over there.

[TOB]

HDY Daily Chart

Day 4 of the rally and we see more advance, this time closing at the tip at 0.90.

Volume a bit lower than yesterday, but still above average.

.80 is now established as proximal support, with .83 a runner up.

It will be interesting to see what happens at resistance at .93 There should be plenty of profit sells and shorts waiting there to pounce, on the other hand, we see how the market likes round numbers such as .70, .80, .90, & $1.10 so perhaps we'll move right to test key resistance?

Those who bought at my first target of .70 can cash in 28% gain at .90, so it's no surprising we saw some selling. But the volume really kicked in at .85 cents, showing that the bulls are buying dips.

The HDY chart remains bullish, and only a sustained break below key support at .70 can change that.

[glassy]

nice

[glassy]

okie dokie

[PoemStone]

Everybody. Going to release all mods & let Index Prime go
or turn it into something else.

[PoemStone]

RGLS. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
-Regulus, in partnership with Sanofi, is developing novel anti-fibrotic therapies targeting microRNAs-
http://finance.yahoo.com/news/regulus-presents-preclinical-data-mir-170000792.html

[PoemStone]

from Bloomberg. after/hours. BRK/A. Berkshire Profit Climbs 72% on Derivatives, Railroad
http://www.bloomberg.com/news/2012-11-02/berkshire-profit-climbs-72-on-derivatives-railroad.html

Warren Buffett’s Berkshire Hathaway Inc. (BRK/A) said profit climbed 72 percent in the third quarter as a stock-market rally helped improve results in the derivatives book and earnings at the railroad climbed.

Net income rose to $3.9 billion, or $2,373 a share, from $2.28 billion, or $1,380, a year earlier, the Omaha, Nebraska- based company said today in a statement. Operating earnings, which exclude some investment results, were $2,057 a share, missing the $2,063 average estimate of three analysts surveyed by Bloomberg.
Sponsored Links

Planning for Retirement?
$500,000 portfolio? Download the guide by Forbes Colu...
www.FisherInvestments.com

iShares Core ETFs
iShares Gives You Access to Low Cost & Tax Efficient ...
www.ishares.com/core

Hottest Penny Stock Pick...
Wallstreet's Hidden Secrets Revealed. Join our newsle...
www.PennyStocks.com
Buy a link

Buffett, 82, made the equity-derivatives bets in the last decade to wager on long-term gains in stock-market indexes in the U.S., Europe and Japan. When the benchmarks fall, as they did in last year’s third quarter, Berkshire’s liabilities on the contracts can climb, pressuring earnings.

“The stock market has had a pretty good run year to date,” Cliff Gallant, an analyst at KBW Inc., said in an interview before earnings were released. “I don’t know if I’d count on it to continue.”

Berkshire’s Class A shares fell less than 1 percent to $130,550 at 4:05 p.m. in New York today. The company has advanced 14 percent this year, compared with the 12 percent gain in the Standard & Poor’s 500 Index. (SPX)
Book Value

Book value, a measure of assets minus liabilities, rose to $184.6 billion from $177.4 billion at the end of June.

The loss on equity index put derivatives narrowed to $534 million from $2.09 billion a year earlier. Gains from credit- default contracts, in which Buffett bets on the ability of borrowers to repay debt, were $316 million compared with a loss of $247 million a year earlier.

Buffett’s biggest takeover, railroad Burlington Northern Santa Fe, was completed in 2010 in a $26.5 billion transaction. The business contributed $937 million to earnings, compared with $766 million a year earlier.

Berkshire has been making smaller acquisitions this year as Buffett searches for larger takeovers. The billionaire said he failed to reach an agreement on a deal valued at about $22 billion earlier this year, while his firm has agreed to buy a newspaper in Waco, Texas, a building-insulation maker and food- distributor Meadowbrook Meat Co.

Buffett’s firm agreed to pay about $500 million to buy Omaha-based party-supply retailer Oriental Trading Co., according to a person familiar with the deal who declined to be identified because the details are private. Berkshire announced the deal today without disclosing terms.
Housing Market

Buffett, Berkshire’s chief executive officer, chairman and controlling shareholder, has been positioning his firm for a rebound in housing. The company added to its holdings of Wells Fargo & Co., the largest U.S. home lender, expanded its real estate brokerage and won an auction for the loan portfolio of bankrupt mortgage lender Residential Capital LLC.

The billionaire said in July that the residential real- estate market was improving, even as other parts of the economy flattened out. Among Berkshire’s more than 70 operating units are businesses that make bricks, paint, insulation and manufactured homes.

Housing prices rose 2 percent in August from a year earlier, the biggest gain since July 2010, according to the S&P/Case-Shiller index of property values in 20 U.S. cities. The number of homes for sale in the U.S. dropped 18 percent in September from a year earlier, according the National Association of Realtors website.
Berkshire’s Cash

Berkshire’s cash pile rose to $47.8 billion from $40.7 billion three months earlier.

Berkshire spent $1.18 billion on equities and $2.08 billion on fixed-maturity securities in the quarter. It sold $3.18 billion in stocks and $1.2 billion in bonds.

The insurance segment posted an underwriting profit of $392 million, compared with $1.09 billion a year earlier, when the reinsurance group led by Ajit Jain benefitted from a reduction in estimated liabilities on some contracts written in prior periods. Underwriting profit at the Geico car insurer climbed to $435 million from $114 million.

Buffett has used so-called float, or the insurance premiums Berkshire holds before paying claims, to amass the largest equity stakes in companies including Coca-Cola Co. (KO) and International Business Machines Corp. Berkshire’s stock portfolio was valued at $88 billion on Sept. 30, up from $86.2 billion at the end of June as Wells Fargo gained 3.3 percent in the third quarter and IBM advanced 6.1 percent.
MidAmerican Energy

Utility unit MidAmerican Energy Holdings Co. added $438 million to Berkshire’s profit, compared with $372 million in last year’s third quarter. Earnings from manufacturing, service and retailing units increased to $991 million in the three months ended Sept. 30 from $836 million in the same period in 2011 on gains at manufacturers including Marmon Holdings, the producer of construction materials.

The group of businesses includes engine-additive maker Lubrizol, which was acquired by Berkshire at the end of last year’s third quarter; Marmon; and Fruit of the Loom, which produces underwear and other clothing. Berkshire doesn’t break down results by each business.

[PoemStone]

VRNG video chat.
[Clay Trader]

[simplegreen]

And I hope you have a great weekend as well PS..next week may really be a hoot so get well rested my friend!..Simple

[PoemStone]

Have a great weekend, Prime.

[PoemStone]

Watching this one. NUAN. They sell DRAGON.

[PoemStone]

Another gap today. TRIP.

[PoemStone]

My birthday gift at work was $100 (as pay before taxes).
Guess they want to keep me lined up.
He got it ok'd by the B.O.D.s

I'm am working for about min wage. 23 hours a week.

A small group of us including the director with the b-day/present
may move on to another non-profit in January.

[PoemStone]

HGSH. Looks like it has a chance to Not correct
too much of that new-volume next week.

[PoemStone]

glassy. Nice gap DNDN. Wonder
how much of it will hold up.

[glassy]

HGSH~ UP 12% again today and broke 3.00!

[glassy]

DNDN~ up 21% 4.70 NHOD

[PoemStone]

Today's Nooner & after/hours iBoxed.

[glassy]

berry nice on that one.

[PoemStone]

7:49 am. Pfizer quarterly revenue falls far short of/forecasts.
http://finance.yahoo.com/news/pfizer-quarterly-revenue-fall-far-111939778.html

(Reuters) - Pfizer Inc reported on Thursday quarterly revenue well below Wall Street expectations, on sharply weaker sales of specialty care drugs and a pullback of emerging market revenue.

Results were also hurt by weaker than expected sales of Pfizer's Prevnar vaccine and Lipitor cholesterol fighter, which has been facing cheaper generics since late last year.

The largest U.S. drugmaker earned $3.21 billion, or 43 cents per share, in the third quarter. That compared with $3.74 billion, or 48 cents per share, in the year-earlier period, when the company recorded a $1.3 billion gain on the sale of its Capsugel business.

Excluding special items, Pfizer earned 53 cents per share. Analysts on average had expected 53 cents, according to Thomson Reuters I/B/E/S.

Global sales fell 16 percent to $13.98 billion, well below Wall Street expectations of $14.64 billion.

[PoemStone]

Big Board BIO updates.
StocksDiva
http://investorshub.advfn.com/StocksDiva-Bio-Bin-16112/

Dynavax Technologies Corporation (NASDAQ: DVAX) announced it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under the terms of a collaboration announced in 2006, and Dynavax expects to receive an advance payment of $6 million in the fourth quarter of 2012. Dynavax anticipates the Phase 1 studies will begin in the first half of 2013.

About AZD1419: AZD1419 has been selected to enter formal clinical development based on extensive preclinical studies conducted by Dynavax and AstraZeneca. Under the terms of a previously-announced research collaboration and license agreement, AstraZeneca will provide to Dynavax approximately $20 million in payments to cover the cost of clinical development activities through Phase 2a. If AstraZeneca chooses to advance the program following completion of Phase 2a, Dynavax will receive a $20 million milestone payment, and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma product. Additional remaining milestone payments to Dynavax amount to approximately $100 million. Dynavax will receive royalties on worldwide sales of approved products and will have the opportunity to co-promote the product in the United States.

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) announced positive results from A-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia A. Hemophilia A is a rare inherited disorder that impairs blood coagulation.

Top-line results from A-LONG, a global, multi-center, Phase 3 clinical study of the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc), showed that rFVIIIFc was effective in the control and prevention of bleeding, routine prophylaxis and perioperative management. Recombinant FVIIIFc was generally well-tolerated. Additional analyses of the A-LONG study are ongoing, and the companies anticipate presenting detailed results at a future scientific meeting.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the third quarter ended September 30, 2012.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Wednesday, November 7, 2012.

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products today announced that they have acquired a new cell sorting system from Propel Labs.

Due to complications from the storm affecting the East Coast, Cambrex Corporation (NYSE: CBM) will now report its results of the third quarter ended September 30, 2012 after the market closes Monday, November 5, 2012.

Compugen Ltd. (NASDAQ: CGEN), announced today the discovery and initial validation of two new drug target candidates for monoclonal antibody (mAb) cancer therapy.

Due to the effects of Hurricane Sandy on the Eastern seaboard, CardioNet, Inc. (NASDAQ:BEAT) is postponing the release of its Third Quarter 2012 financial results to Monday, November 5 at 4 PM Eastern Time.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of the Phase 3 CB-5945 opioid-induced constipation (OIC) Ascent program with the enrollment of the first patient in the long-term safety study, which is one of four registrational studies in patients with chronic non-cancer pain.

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), will present 13 abstracts at the American Society of Nephrology (ASN) Kidney Week in San Diego, November 1-4.

Emergent BioSolutions Inc. (NYSE: EBS) announced today the initiation of a Phase 1b study (Protocol 16009) of TRU-016 in combination with rituximab for patients with previously untreated chronic lymphocytic leukemia (CLL). TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate (TAF; formerly referred to as GS-7340), an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.

Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced it has signed an updated license agreement with Intuitive Surgical (NASDAQ: ISRG).

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the 2012 Brean Capital Life Sciences Summit on November 7, 2012 in New York City.

InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter and first nine months 2012 financial results at the close of the U.S. markets on Wednesday, November 7, 2012.

Medidata Solutions (NASDAQ: MDSO) has been selected by Sanofi, one of the world’s leading pharmaceutical companies, as the clinical technology standard for clinical data collection, management and reporting and performance-enhancing analytics across its entire R&D organization.

Medidata Solutions (NASDAQ: MDSO), a leading global provider of cloud-based drug development solutions that optimize the efficiency of clinical development, today announced its financial results for the third quarter of 2012, and provided detailed financial guidance for the fourth quarter and full year 2012.

NeoGenomics, Inc. (NASD OTC QB: NGNM), a leading provider of cancer genetic testing services today reported its results for the third quarter 2012.

NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the third quarter of 2012.

Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Wednesday, November 7, 2012 at 4:30 p.m. Eastern Time to discuss its financial results and provide a review of its pipeline of products in development.

Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended September 30, 2012 on Wednesday, November 7, 2012 after the market closes.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its collaborator, Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced that the European Commission has granted conditional marketing authorization for ADCETRIS (brentuximab vedotin).

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the third quarter 2012 financial results, provide an update on the Company's business, and discuss expectations for the future.

Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of data at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 6-9, 2012, in Dublin, Ireland.

[PoemStone]

PBH. Ascending triangle. 6:00 am. Reports 53.4% Revenue Increase & Record Earnings for Second Quarter of Fiscal 2013
Full Year EPS Guidance Increased; Divestiture of Phazyme® Announced
http://finance.yahoo.com/news/prestige-brands-holdings-inc-reports-100000720.html
http://finance.yahoo.com/news/prestige-brands-holdings-inc-reports-100000720.html

[PoemStone]

ANSS. 7:27 am. Reports Record Third Quarter Results That Highlight Strong Margins And EPS Overperformance
http://ih.advfn.com/p.php?pid=nmona&article=54787501

GAAP revenue of $196.9 million and non-GAAP revenue of $199.8 million
GAAP diluted earnings per share of $0.54 and non-GAAP diluted earnings per share of $0.74
Operating cash flows of $70.4 million
GAAP operating profit margin of 37.4% and non-GAAP operating profit margin of 51.0%

[glassy]

NFLX~3:00 PM Netflix (NFLX +11.2%) amends its 10-Q to report a 348% Y/Y increase in its International content expenses in Q3, instead of the 14% originally disclosed by the company.

[glassy]

forex in the ibox- nice!

[glassy]

SG is absolutely one of THE best traders I know of-stunning in his TA always.

[glassy]

well, lets hope he pads it- ha ha

[glassy]

of course it was absolutely you I was referring to-ha ha. I think I am an old dog and have not gotten motivated to try a new trick but I am sure I should. I love that its not for the faint of heart- my motto is : Vivere-Dare to Live! ( Andrea Bocelli)
When our oldest son married, that was the Mother/Son dance I chose. both sons are AD military still and hes doing explosives so I prolly did not have to tell him that butttttttttt haha

[PoemStone]

Hey glassy, nice friend there. simple.

[PoemStone]

after/hours, on the iBox now.

[simplegreen]

Good afternoon glassy!..was snooping around and eavesdropping after PoemStone paid a brief visit to the Green Room .. lo&behold heres one my oldest and dearest friends on Ihub!!Hope life and equities heve been treating you well...think of you often especially since every morning when I get my coffee in the kitchen I have a reminder of you with the precious gift you gave the wife and myself hanging in the window!No doubt you were referring to me on the good friend totally into FOREX...still am and theres no looking back..just to good a deal to pass up IMO.Been kicking that monsters tail on a regular basis for quite a while now..its not for the faint of heart but I am a confirmed FOREX A Holic(LOL)
Its taught me more about charting and trading than all my equity days rolled together.Not gonna bug you anymore to try it tho but enjoy a chance to rekindle an old and dear friendship...Simple

[PoemStone]

glassy. I haven't tried forex either. But there it is now
for us all to learn something.
I'd mark that board and get closer to them.

[PoemStone]

Birthday Thanks. They had Pizza delivered (for me)to us at work.
Stuffed. Director said he'd have a birthday present for me Friday (payday).....

[glassy]

have a good friend who's totally into forex but i have not tried it- or really figured it out...

[glassy]

yes, I think the repercussions are hure

[glassy]

Happy B ay- ha ha!

[PoemStone]

New Board picture & link on iBox. Forex trading.

[PoemStone]

!!!!!Birthday Room!!!!!
http://investorshub.advfn.com/!!!!!-Birthday-Room-!!!!!!-23246/

[PoemStone]

MDSO. Bookings in the quarter were the second highest in the company’s history, with year to date activity ahead of the entire full year of 2011 by 34%, exceeding internal expectations.
Record revenues for the quarter of $55.8 million increased 21% year over year, exceeding the company’s long-term revenue growth target of 20%.
For the quarter, non-Rave revenues increased 142% year over year and 27% sequentially. Year to date, non-Rave revenues grew 145% year over year.
Total customers were up 28% over last year, to a record 333, a net increase of 72 customers year over year. Six current customers upgraded to enterprise deals from study-by-study arrangements in the quarter, highlighting the increasing adoption of the Medidata platform. These new enterprise customers include Sanofi, one of the world’s leading pharmaceutical companies; Otsuka Pharmaceutical, one of Japan’s top 10 pharmas; and a Top 5 contract research organization.
Current customers contracting for additional products grew by 50% over last quarter, showing continued growth in the Medidata Clinical Cloud platform. Customers with multiple products now account for over 35% of the total customer base.
http://finance.yahoo.com/news/medidata-solutions-reports-third-quarter-110000887.html

[PoemStone]

SGEN. Seattle Genetics Announces ADCETRIS® Receives European Commission Conditional Marketing Authorization
Conditional Marketing Authorization Triggers Milestone Payments to Seattle Genetics Totaling $25 Million
http://finance.yahoo.com/news/seattle-genetics-announces-adcetris-receives-110000356.html

[PoemStone]

ICFI. ICF International Awarded $9.2 Million Contract with Centers for Disease Control and Prevention
http://finance.yahoo.com/news/icf-international-awarded-9-2-110000927.html

[PoemStone]

ENZN. reported net income of $4.2 million, or $0.08 diluted earnings per share, for the third quarter of 2012, as compared to a net loss of $9.1 million, or $0.19 diluted loss per share
http://finance.yahoo.com/news/enzon-reports-third-quarter-2012-110000114.html

[PoemStone]

MDSO. Sanofi Selects Medidata Clinical Cloud as a Technology Standard Across Global R&D Organization

Top 5 Pharma Chooses Medidata Platform for Cutting-Edge Productivity, Cost Savings and SaaS Ease-of-Use to Benefit Multiple Trial Areas
http://finance.yahoo.com/news/sanofi-selects-medidata-clinical-cloud-103000554.html

[PoemStone]

Abaxis Announces Exclusive Distribution Agreement with Abbott
Abbott to market, sell and distribute the Piccolo® Xpress and its reagent discs for point-of-care blood chemistry analysis in the human medical market
http://finance.yahoo.com/news/abaxis-announces-exclusive-distribution-agreement-090000600.html

[PoemStone]

glassy. I don't think I realized how
big a problem it all is for the markets.

[glassy]

.S. stock markets plan to reopen Wednesday

U.S. stock exchanges are looking at opening on Wednesday after monster storm Sandy receded from New York, sources said, and the New York Stock Exchange is testing a new plan to help resume trading.

U.S. stock markets were closed on Monday and Tuesday. At least some market participants believe that opening on Wednesday is critical, because many traders need prices to value their portfolios at the end of the month.

The bond markets are also closed on Tuesday, with traders aiming to reopen on Wednesday.

JPMorgan Chase & Co, the largest U.S. bank, expects many employees will be able to return to buildings starting on Wednesday, according to an internal memo obtained by Reuters.

Plans to resume trading will be complicated by the lingering effect of the storm on New York. Sandy is the worst storm to hit the city since at least 1938, and brought a record storm surge that could hobble New York’s subway system for days.

If markets do open on Wednesday, there could be heavy selling, as investors whose fiscal years end in October look to get tax benefits from shedding losing stocks, said Eric Marshall, a mutual fund manager at Hodges Capital in Dallas.

If NYSE Euronext’s New York Stock Exchange headquarters and trading floor are unavailable on Wednesday, trading in NYSE-listed securities will be executed on the Arca exchange, the exchange operator said in a notice issued to traders late Monday. ()

NYSE Arca was to offer firms the ability to test the opening and closing auctions on NYSE Arca on Tuesday from 8 a.m. Eastern time (ET) (1200 GMT) until noon ET, the exchange said.

Opening auctions will run at 9:30 a.m. ET and closing auctions will run at noon, the exchange said.

“We stress that, as of now, there has been no damage to the NYSE Euronext headquarters that would impair trading floor operations,” NYSE said in the notice.

The NYSE’s headquarters is a few hundred yards (meters) up the street from areas of lower Manhattan that have been evacuated.

Nasdaq OMX said in a trader alert late on Monday it would operate its production system in a testing capacity from 7:30 a.m. (1130 GMT) to 12 p.m. (1600 GMT). ()

The NYSE had said on Sunday afternoon it planned to close its trading floor and to move all trading to its electronic market.

It backtracked on that idea after traders and regulators expressed concern about moving everything to the all-electronic venue, a plan tested on March 31 but never used live, given the difficulties and low staffing levels due to the storm.

[glassy]

oh wow- really ? Well HAPPY "BIRFDAY" in about 2 hours